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Abstract
Background: Deciding whether to discontinue antibiotics at early review is a cornerstone of hospital antimicrobial
stewardship practice worldwide. In England, this approach is described in government guidance (‘Start Smart then
Focus’). However, < 10% of hospital antibiotic prescriptions are discontinued at review, despite evidence that 20–
30% could be discontinued safely. We aimed to quantify the relative importance of factors influencing prescriber
decision-making at review.
Methods: We conducted an online choice experiment, a survey method to elicit preferences. Acute/general
hospital prescribers in England were asked if they would continue or discontinue antibiotic treatment in 15
hypothetical scenarios. Scenarios were described according to six attributes, including patients’ presenting
symptoms and whether discontinuation would conflict with local prescribing guidelines. Respondents’ choices were
analysed using conditional logistic regression.
Results: One hundred respondents completed the survey. Respondents were more likely to continue antibiotics
when discontinuation would ‘strongly conflict’ with local guidelines (average marginal effect (AME) on the
probability of continuing + 0.194 (p < 0.001)), when presenting symptoms more clearly indicated antibiotics (AME of
urinary tract infection symptoms + 0.173 (p < 0.001) versus unclear symptoms) and when patients had severe frailty/
comorbidities (AME = + 0.101 (p < 0.001)). Respondents were less likely to continue antibiotics when under no
external pressure to continue (AME = − 0.101 (p < 0.001)). Decisions were also influenced by the risks to patient
health of continuing/discontinuing antibiotic treatment.
Conclusions: Guidelines that conflict with antibiotic discontinuation (e.g. pre-specify fixed durations) may
discourage safe discontinuation at review. In contrast, guidelines conditional on patient factors/treatment response
could help hospital prescribers discontinue antibiotics if diagnostic information suggesting they are no longer
needed is available.
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Background
Antimicrobial resistance (AMR) is a growing global public
health problem that threatens to undermine many advances
of modern medicine [1]. Reducing unnecessary antibiotic
prescribing and thus selective pressure on bacteria to de-
velop resistance is a key strategy to combat AMR [2, 3].
In the English National Health Service (NHS), reduc-
tions in antibiotic use have been achieved in primary care
by raising the threshold for starting patients on antibiotics
[4, 5]. Given the need to initiate antibiotic therapy ur-
gently in life-threatening infection, limiting antibiotic
overuse in hospitals depends on prescribers undertaking
an early antibiotic prescription ‘review and revise’ at
around 48–72 h after a patient starts antibiotic treatment.
In England, this approach is supported by ‘Start Smart
then Focus’ guidance [6], and in the USA, by ‘Antibiotic
Time Outs’ [7]. However, antibiotic prescribing has con-
tinued to increase in NHS hospitals, both overall and in
terms of certain broad-spectrum, intravenous agents (e.g.
quinolones and 3rd, 4th and 5th generation cephalospo-
rins) [5]. Although hospitals only account for around 1/5
of total antibiotic prescribing, this increase is a major con-
cern because this is where most broad-spectrum agents
are used. Such agents have the greatest potential to drive
resistance and cause adverse drug reactions [8].
The ability to ‘review and revise’ antibiotic prescriptions
is a key competency for healthcare professionals who pre-
scribe antibiotics in hospitals [9]. Prescribers may choose
to change route or duration of therapy, but only a decision
to stop treatment quantitatively reduces antibiotic expos-
ure. In current practice, prescribers frequently do not se-
lect this option when it would be safe to do so. For
example, while up to 20–30% of initial prescriptions
amongst acute medical admissions could be stopped
safely, in routine practice, fewer than 10% are typically
stopped [10–12]. In a systematic review of in-hospital
antibiotic prescribing decisions (including both initial pre-
scribing and de-escalation decisions), sociocultural and
behavioural factors, such as fear of adverse health out-
comes for patients, intolerance of uncertainty, professional
hierarchy and beliefs on the applicability of antibiotic pre-
scribing guidelines, were found to be likely to play a role
in these decisions [13]. However, it is likely that the deter-
minants of decisions to start antibiotic treatment and de-
cisions taken at review differ, so that decisions specifically
to de-escalate antibiotic treatment are a subset of these
factors. Furthermore, there is a lack of quantitative evi-
dence on the relative weights of such determinants,
knowledge of which could enable efficient design and im-
plementation of stewardship interventions [13].
This study therefore aimed to quantify the relative im-
portance of key factors influencing prescribers’ decisions
on whether to stop or continue antibiotics at ‘review and
revise’. To do so, we conducted an online choice
experiment, a survey method widely used in health eco-
nomics [14–16]. The method involves eliciting preferences
for alternative healthcare options by asking respondents to
make trade-offs between key attributes of these options.
Methods
Survey development
The choice survey was developed in accordance with
good practice guidelines [17]. The sampling frame was
healthcare professionals in the UK, who make antibiotic
prescribing decisions in acute/general hospital medicine.
There were no other inclusion criteria. We recruited
participants through the Society for Acute Medicine
(SAM), the national representative body for all clinicians
working in acute medical units, and through three of the
thirteen postgraduate deaneries, which manage post-
graduate medical education in England. We selected one
in the South of England (Kent Surrey and Sussex), one
in Central England (Thames Valley) and one in the
North of England (North East and Cumbria).
The selection of key factors (‘attributes’) likely to influ-
ence ‘review and revise’ prescribing decisions was in-
formed by a literature review that we undertook
(Additional file 1) and qualitative interviews undertaken
as part of the ARK-Hospital research programme [10].
The ARK-Hospital programme is developing a complex
behavioural intervention that aims to safely increase
antibiotic stopping rates for acute/general medical pa-
tients admitted to the hospital. Ultimately, to conduct
our choice experiment, we needed to compile a list of
between around 4 and 8 attributes that captured the es-
sence of the ‘review and revise’ decision. As in all choice
experiments, deciding this final list of attributes, and the
precise wording of those attributes, inevitably required
an element of judgement [17]. Based on the ARK-
Hospital qualitative interviews and the literature review,
and drawing on many decades of experience of antibiotic
de-escalation decisions within the team, we identified six
attributes that we believed captured the central issues
driving ‘review and revise’ prescribing decisions (Table 1).
We deliberately focused on attributes that were either
known at patient presentation in the hospital or were
generalizable across patients. This was because individ-
ual responses to treatment are very specific (as reflected
in a large number of different aspects of response men-
tioned in respondent comments, Additional file 10), and
such heterogeneity could not be adequately captured in
the attribute descriptions. Levels were identified for each
attribute, informed by the qualitative interviews and
clinical expertise within the study team (Table 1).
Constructing the choice questions
In each choice question, respondents were presented
with the same hypothetical situation (Fig. 1), in which
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they were asked to imagine they were reviewing the
treatment of a patient admitted to hospital 72 h ago and
in whom antibiotic treatment had been initiated within
2 h of their hospital admission.
Respondents were asked to review a table of information
on the status of the patient, the likely consequences of
continuing and discontinuing antibiotic treatment, and
the potential pressures related to this clinical decision (i.e.
the six attributes and their levels). They were asked
whether, given this information, they would choose to
continue or discontinue antibiotic treatment (to state their
preference). Respondents were presented with a total of
15 choice questions (considered an acceptable number)
[14, 18, 19], with the levels of attributes varying across
each question. The attribute levels presented in each ques-
tion were generated using experimental design computer
software, Ngene (Additional file 2) [20].
Survey presentation
The choice experiment was conducted as an online survey
(Additional file 3). Respondents viewed a participant infor-
mation page and provided informed consent by answering
a series of questions affirmatively (Additional file 3). They
were then presented with background information,
instructions on how to complete the survey and a descrip-
tion of the attributes and levels (described in the survey as
‘categories of information’). Next, respondents were asked
to rank the six attributes in terms of their relative import-
ance when making their decisions and to complete a prac-
tice choice question (Fig. 1). This practice question was
designed so that the levels presented for each factor
should push respondents as far as possible in the direction
of choosing to discontinue antibiotics. Respondents then
completed the 15 choice questions and undertook a sec-
ond ranking exercise to investigate whether their prefer-
ences had changed during survey completion. Information
was also collected on respondent characteristics, including
age, gender, primary specialty and clinical grade. Finally,
respondents were given an opportunity to offer comments
about the survey.
Piloting and data collection
The survey was piloted amongst twelve healthcare pro-
fessionals who met the inclusion criteria prior to launch.
Respondent choices in the pilot were used to develop a
preliminary model of review and revise decisions, in
order to fine-tune the experimental design to maximise
the information provided whilst minimising participant





Symptoms indicating a urinary
tract infection, with kidney
pain.
Fever, cough and possible
pulmonary infiltrates on chest X-
ray.
Off-legs and confused. Possible
urinary tract infection, possible
lower respiratory tract infection.
Might have experienced a fall






Whether early discontinuation of
antibiotic treatment within 72 h
of treatment initiation would be
in conflict with local antibiotic
guidelines [CONFLICT]
Early discontinuation would
strongly conflict with local
antibiotic guidelines.
Early discontinuation would
somewhat conflict with local
antibiotic guidelines.
Early discontinuation would not
conflict with local antibiotic






Risk of significant harm arising
from continued antibiotic
treatment [CONTINUE RISK]
Likely. In 30 cases out of every
100 like this, the patient will
experience an adverse effect
from continued antibiotic
treatment.
Somewhat likely. In 10 cases out
of every 100 like this, the patient
will experience an adverse effect
from continued antibiotic
treatment.
Negligible. In 1 case out of every
100 like this, the patient will







Risk of significant harm arising
from discontinuing antibiotic
treatment [STOP RISK]
Likely. In 30 cases out of every
100 like this, the patient will
have a relapse, recurrence or
readmission if antibiotic
treatment is discontinued.
Somewhat likely. In 10 cases out
of every 100 like this, the patient
will have a relapse, recurrence or
readmission if antibiotic
treatment is discontinued.
Negligible. In 1 case out of every
100 like this, the patient will have
a relapse, recurrence or







Premorbid condition of the
patient [PREMORBID]
The patient has severe frailty
and comorbidities.
The patient has moderate frailty
and comorbidities.
The patient was previously fit and






Level of external pressure to
continue antibiotic treatment
[EXTERNAL PRESSURE]
There is no external pressure to
continue antibiotic treatment.
There is some external pressure to
continue antibiotic treatment.
There is heavy external pressure to
continue antibiotic treatment






1Ngene codes the top level as the base variable, rather than the bottom variable. Factor names are in square brackets
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Fig. 1 Hypothetical choice situation presented to respondents—practice question
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burden. The pilot data were not included in the final
analysis.
Members of SAM and trainees in acute/general medicine
registered with the postgraduate deaneries were contacted by
email with information about the study, a request to partici-
pate and a link to the survey (Additional file 4). The survey
was generated and data collected using LimeSurvey, a statis-
tical survey web application. Data collection took place
through June 2018–January 2019. We aimed to recruit at
least 100 respondents, which is the minimum number indi-
cated by a widely used rule of thumb [21].
Data analysis
Data analysis used Stata version 15. We estimated a con-
ditional logistic regression model, which includes a fixed
effect at the level of the respondent, capturing any unob-
served heterogeneity between respondents. However,
this model also assumes that attribute coefficients are
the same across respondents. As a robustness check, we
therefore estimated a mixed effects logistic model, which
allows the attribute coefficients to vary across individ-
uals, i.e. to have ‘random effects’.
Both models estimated the impact of the different at-
tributes and levels on the probability of choosing to con-
tinue antibiotic treatment. To help with interpretation,
the average marginal effect (AME) of each attribute level
on the probability of choosing ‘continue’ was calculated.
For the categorical attribute levels (levels for presenting
symptoms, whether discontinuation would conflict with
local prescribing guidelines, premorbid condition of pa-
tient, level of external pressure to continue antibiotics),
the AME estimates how much higher/lower the prob-
ability of continuing was at this attribute level than the
probability at the attribute’s base level. For the continu-
ous variables (risk of continuing/risk of discontinuing),
the AME estimates how much higher/lower the prob-
ability of continuing was for a 1% higher risk.
Respondent characteristics cannot be included in a
binary logistic model with respondent-level fixed effects.
However, they may be associated with the total number
of occasions respondents chose to ‘continue’ versus ‘dis-
continue’ antibiotics. We investigated this using ordered
probit models, where the dependent variable was the
number of choice questions in which respondents chose
to ‘continue’ antibiotics.
Free-text comments were analysed using inductive
content analysis—that is, the categories were suggested
by the text rather than an imposed framework [22].
Results
The survey was completed by 101 people, one of whom
was not based in the UK and so was excluded in our
analysis. Eighty-two of the 100 included respondents
were aged 25–44 years, and acute/general medicine was
the primary specialty for 57/99 (58%) (Table 2). Further
respondent characteristics are shown in Table 2 and
Additional file 5: Personality questions [23]. The respon-
dents listed as ‘non-medical prescriber’ and ‘other’ were
mostly specialists in acute/general medicine, and all re-
ported that they made antibiotic review decisions mul-
tiple times per month. It therefore seemed reasonable to
include them in the sample.
There were minor differences in how respondents
ranked the attributes before and after completing the
choice questions (Additional file 6). Beforehand, the
most important attribute was ‘patient’s presenting symp-
toms’, followed by ‘risk of significant harm arising from
discontinuing antibiotic treatment’. The least important
attribute was ‘level of external pressure to continue anti-
biotic treatment’. The attribute rankings remained the
Table 2 Descriptive statistics
Variable n (%)
Male 49 (49%)
Age of respondents (n = 100)
Under 25 years 3 (3%)
25 to 34 years 49 (49%)
35 to 44 years 33 (33%)
45 to 54 years 14 (14%)
55 to 64 years 1 (1%)
65 years and over 0 (0%)
Number of beds in hospital (n = 98)
Less than 500 21 (21%)
500–1000 47 (48%)
More than 1000 30 (31%)
Main occupation (n = 98)
Consultant 30 (31%)
Staff grade or associate specialist 4 (4%)
Pre-registration doctors 9 (9%)
Core medical trainee 16 (16%)
Specialty registrars 35 (36%)
Non-medical prescriber (e.g. nurse or pharmacist) 1 (1%)
Other occupations 3 (3%)
Primary clinical specialty (n = 98)
Acute or general medicine 57 (58%)
Microbiology or infectious diseases 14 (14%)
Non-infection related medical specialty 9 (9%)
No primary clinical specialty 3 (3%)
Other 15 (15%)
Risk score out of 10, mean (SD) (n = 97)1 6.1 (1.8)
1SD standard deviation. Respondents were asked to rate their attitude to risk
on a 0 to 10 scale, where 0 means ‘risk averse’ and 10 means ‘fully prepared
to take risks’
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same after completing the survey, except that the order
of the first and second most important reversed.
Choice experiment results
All respondents completed all 15 choice questions, yield-
ing 1500 choices in total. ‘Continue’ was selected in
1032 (69%) choices. The minimum number of times any
respondent chose to ‘continue’ antibiotics across the 15
choice questions was 3, and the maximum was 15 (2 re-
spondents) (Fig. 2). The number of choices to continue/
discontinue varied by question from 99/1 to 29/71, with
some close to 50/50 (Additional file 7: Table S3).
The conditional logistic model for choosing to continue
versus discontinue antibiotics with respondent-level fixed
effects (Table 3) had a McFadden pseudo-R-squared value
of 0.320, indicating an ‘excellent fit’ ([24], p. 35), with all
coefficients having the expected sign indicating face valid-
ity. For each attribute, at least one level was highly signifi-
cant, with sizable AMEs. The largest AME came from
conflict with local guidelines, with respondents more likely
to continue antibiotics when early discontinuation would
‘strongly conflict’ with local guidelines (AME on the prob-
ability of continuing + 0.194 (p < 0.001) versus ‘no con-
flict’). However, they were no more/less likely to continue
antibiotics when there was only ‘some conflict’. The next
highest AME was for the ‘presenting symptoms’ level most
strongly supporting the need for antibiotics (AME of typical
symptoms of urinary tract infection + 0.173 (p < 0.001) ver-
sus unclear symptoms). Respondents were also more likely
to continue antibiotics when patients had severe frailty and
comorbidities (AME=+ 0.101 (p < 0.001) versus patients
previously fit and well). Conversely, they were less likely to
continue antibiotics when there was no external pressure to
do so (AME=− 0.101 (p < 0.001) versus heavy pressure). De-
cisions were also influenced by the competing risks of con-
tinuing treatment (e.g. antibiotic resistance) (AME of 1%
point higher risk − 0.013 (p < 0.001)) versus discontinuing
(e.g. treatment failure) (AME of 1% point higher risk + 0.026
(p < 0.001)). Sensitivity analyses using mixed effects logistic
models were broadly similar, with comparable AMEs but
poorer model fit (Additional file 8).
Being a consultant was associated with being less likely
to continue prescribing antibiotics, i.e. in terms of the
total number of times respondents chose to continue an-
tibiotics across the 15 choice questions (Additional file 9).
However, we did not find evidence for modification of
the effects of attributes in the conditional logistic model
in Table 3 by being a consultant versus other grades
(interaction p > 0.06 for all attribute levels). Prescriber
personality traits (Additional file 5) were also associated
with prescribing choices across the 15 questions. Extra-
version was associated with being more likely to choose
to continue antibiotics; agreeableness was associated
with being less likely to continue antibiotics
(Additional file 9).
Comments from respondents
Most respondents found the survey neither easy nor difficult
to complete: the median (IQR) difficulty score was 4 (3–5)
on a 1–7 scale (where 1 = very easy and 7 = very difficult).
One third of the respondents left feedback on the sur-
vey (Additional file 10), falling into several categories
(Table 4). The most common category stressed the im-
portance to review and revise decisions of additional
Fig. 2 Histogram of number of questions in which respondents chose to continue antibiotics
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clinical information not captured in our experiment,
particularly regarding response to treatment, and
whether the patient was improving or deteriorating at
the ‘review and revise’ stage.
Discussion
Using a choice experiment, we have quantified the rela-
tive importance of attributes likely to play a key role in
decisions to (dis) continue antibiotics at the time of ‘re-
view and revise’ amongst acute/general medical patients.
The choice of attributes included was informed by
literature review and qualitative interviews, combined
with experience within the team. The attribute level with
the largest marginal effect on prescribing was ‘early dis-
continuation of antibiotics being in ‘strong conflict’ with
local guidelines’. However, early discontinuation ‘some-
what conflicting’ with local guidelines was not signifi-
cant. This suggests interventions to make guidelines less
prescriptive about antibiotic continuation could help in-
crease appropriate early discontinuation.
In NHS hospitals, antibiotic guidelines do not gener-
ally acknowledge the uncertainty that exists prior to the
Table 3 Conditional logistic regression analysis








UTI symptoms with kidney pain 1.132 0.155 0.829 1.436 0.173 < 0.001
Fever, cough and possible pulmonary infiltrates on chest X-
ray
0.246 0.108 0.034 0.459 0.038 0.023
Unclear symptoms3 − 1.379 – – – – –
CONFLICT WITH GUIDELINES
Strongly conflict 1.275 0.131 1.018 1.532 0.194 < 0.001
Somewhat conflict 0.073 0.089 − 0.101 0.248 0.011 0.411
No conflict3 − 1.348 – – – – –
CONTINUE RISK − 0.085 0.012 − 0.108 − 0.061 − 0.013 < 0.001
STOP RISK 0.172 0.017 0.139 0.205 0.026 < 0.001
PREMORBID CONDITION
Severe frailty and comorbidities 0.660 0.138 0.390 0.930 0.101 < 0.001
Moderate frailty and comorbidities 0.300 0.098 0.108 0.492 0.046 0.002
Fit and well3 − 0.960 – – – – –
EXTERNAL PRESSURE
No pressure − 0.660 0.097 − 0.851 − 0.469 − 0.101 < 0.001
Some pressure − 0.104 0.094 − 0.289 0.080 − 0.016 0.268
Heavy pressure3 0.764 – – – –





1AME is the average marginal effect of each factor level on the probability of choosing to continue. For the categorical factor levels, this indicates how much
higher/lower the probability of continuing was at this attribute level than the probability at the factor’s base level. For the continuous variables (risk of
continuing/risk of discontinuing), the AME indicates how much higher/lower the probability of continuing was for a 1% higher risk. AIC Akaike Information
Criterion, BIC Bayesian Information Criterion, CI 95% confidence interval. p p value of coefficient, SE standard error clustered at the respondent level
2Attribute descriptions: SYMPTOMS = patient’s presenting symptoms (1 = UTI and kidney, 2 = fever cough and funny X-ray, 3 = unclear [base level]); CONFLICT
WITH GUIDELINES = whether early discontinuation of antibiotic treatment within 72 h of treatment initiation would be in conflict with local antibiotic guidelines
(1 = strongly conflict, 2 = somewhat conflict, 3 = not conflict [base level]); CONTINUE RISK = risk of significant harm arising from continued antibiotic treatment,
expressed as a percentage; STOP RISK = risk of significant harm arising from discontinuing antibiotic treatment, expressed as a percentage; PREMORBID
CONDITION = premorbid condition of the patient (1 = severe frailty and comorbidities, 2 = moderate frailty and comorbidities, 3 = fit and well [base level]); and
EXTERNAL PRESSURE = level of external pressure to continue antibiotic treatment (1 = no pressure, 2 = some pressure, 3 = heavy pressure [base level]). The sample
size arises from 98 respondents times 15 choice questions. The 2 respondents who chose ‘continue’ in all 15 choice questions were omitted because of the lack of
variation in their responses
3These attributes were effects-coded. The coefficients of the base levels (unclear symptoms, no conflict, fit and well and heavy pressure) were calculated as the
negative sum of the coefficients of the other levels
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‘review and revise’ decision, but make didactic state-
ments stipulating durations, such as ‘duration: 7 days’,
which are not likely to be appropriate for many patients
[25]. Furthermore, quality improvement assessments of
antibiotic prescribing routinely audit how often prescrip-
tions match guidelines. Prescribers are therefore con-
fronted with a situation in which a patient has been
started on antibiotics, with an indication recorded for
which guidelines specify a duration, and hence, stopping
antibiotics early will lead to a poor audit outcome.
Guidelines might better support bedside stewardship de-
cisions if they made duration recommendations only for
patients in whom ‘review and revise’ has determined that
antibiotics are truly indicated. They could also recognise
that clinical response should be considered, for example,
replacing ‘duration: 7 days’ with ‘duration: up to 7 days
depending on patient factors and treatment response’.
This could provide guidance to (often relatively junior) cli-
nicians on duration decisions, minimising potential for
poor patient outcomes, without unnecessarily overriding
their clinical judgement. The content analysis highlighted
the importance of treatment response, whether patients
are improving or deteriorating. This suggests respondents
are already using clinical judgement when making deci-
sions; guidelines which recognise this might empower
them to discontinue antibiotics more often.
Consultant respondents were significantly more likely
to discontinue antibiotics, consistent with previous stud-
ies suggesting junior doctors focus more on conservative
prescribing practice to avoid censure by senior col-
leagues [26]. However, there was no significant
interaction between consultant status and any of the at-
tribute levels in the prescribing decision. This suggests
that consultants are more prone to discontinue antibi-
otics in general, rather than any of these six attributes
influencing their decisions differently to other grades.
The competing risks of continuing versus discontinu-
ing antibiotics both played an important role in review
decisions. However, a higher risk of discontinuing af-
fected decisions about twice as much as the same higher
risk from continuing. This supports the view that the
risk from continuing antibiotics is much less salient in
clinical practice than the risk from discontinuing them
[27]. One interpretation might be that it may be valuable
to make risks of continuing unnecessary antibiotics, e.g.
from Clostridioides difficile diarrhoea or adverse drug re-
actions [8], more salient to clinicians. However, as sev-
eral respondents noted, in the choice experiment, the
risks from continuing and discontinuing antibiotics were
quantified and made explicit, whereas in clinical prac-
tice, these risks are harder to quantify. Without this in-
formation, factors such as presenting symptoms and
response to treatment may be used to infer these risks.
We found respondents were much less likely to con-
tinue antibiotics when there was no external pressure to
do so—10% less likely than when faced with ‘heavy’ ex-
ternal pressure. This contrasts with responses to the at-
tribute ranking exercise, where external pressure was
ranked as the least important attribute. The ability of
choice experiments to better capture underlying prefer-
ences—and thus actual decision-making—versus direct
questions about preferences is considered one of their
Table 4 Categories of respondent comments
Category Description of category content
Importance of clinical information, especially response to
treatment
This category highlighted the importance to review and revise decisions of signs that
patients are improving or deteriorating following treatment. Such comments referred, for
example, to the importance of the information provided by clinical assessment and
observations, such as temperature, culture results and inflammatory markers.
Somebody else’s problem This category expressed the view that antibiotic use in secondary care contributes
relatively little to antibiotic resistance and that the focus of antibiotic stewardship should
be elsewhere, such as primary care, agriculture or in other countries.
Critique of the study Comments in this category criticised elements of the choice questions. Examples
included an assertion that chest X-rays produce clear results and that describing the re-
sults in our factor-level description as indicating ‘possible infiltrates’ was ‘daft’.
Didactic guidelines This category contained comments on the guidelines being too risk averse and
reluctance not to follow the guidelines ‘when the stakes are high’ unless advised by a
senior colleague.
The role of external pressure depends on the context and
on where the pressure is coming from
A comment suggested that whether external pressure to continue antibiotics had an
effect on review and revise decisions depends on where the pressure is coming from—
for example, pressure from a consultant would have much more impact than pressure
from patients’ relatives.
In real-life levels of harm from continuing/discontinuing
antibiotics are harder to quantify
This category expressed the view that in real clinical practice, the actual risk levels of
continuing/discontinuing antibiotics are not clear-cut as presented in our choice experi-
ment. Instead, they are ambiguous and must be inferred, for example, the degree of
confidence in the diagnosis.
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key strengths [28]. It is possible that respondents were
either unaware of the extent to which pressure is an in-
fluence or, due to social desirability bias, did not want to
admit it in the ranking exercise. This raises questions as
to whether external pressure to continue antibiotics can
be reduced, or whether the way prescribers respond to
external pressure can be changed, e.g. through training.
One limitation however is that different respondents
may have interpreted pressure in different ways. One re-
spondent commented that the relevance of this attribute
depends on where the pressure is coming from; it would
be extremely important if it was coming from within the
team, especially a consultant, but much less so if from
patients’ relatives.
Previous studies have identified sociocultural and behav-
ioural factors likely to play a role in hospital antibiotic pre-
scribing decisions, including attitudes to guidelines and
tolerance of risk of undertreating infections [13]. Quanti-
tative evidence on the relative importance of different fac-
tors can support the design and implementation of more
efficient stewardship interventions, by directing interven-
tions to target the most influential factors [13]. To our
knowledge, this is the first study to quantify the relative
importance of such factors.
Our study also has limitations. First, though the research
question is of wider relevance, the setting for the study
was the NHS in England. In other settings, the factors
driving early discontinuation of antibiotics may vary. For
example, in the USA and elsewhere, procalcitonin mea-
surements are used widely to guide discontinuation deci-
sions in some clinical scenarios [29, 30]. This is not true
currently of UK practice outside critical care units. Sec-
ond, reported actions in a survey may not reflect actual
choices in clinical practice, though asking respondents to
make trade-offs rather than state absolute preferences
may partially mitigate this limitation. Third, our sample
size may be considered small, but choice experiments
such as this one typically require smaller sample sizes than
many other types of regression-based analyses. In essence,
this is because each respondent completes a number of
choice tasks (15 in this study), which multiplies the
amount of information captured from each respondent.
Thus, sample sizes of 100 or lower are not unusual [31].
Fourth, though informed by qualitative interviews and lit-
erature review, deciding which factors to include in the
choice experiment inevitably required an element of
judgement, and the factors we used to characterise the ‘re-
view and revise’ decision are necessarily a simplification.
Several respondents said that in clinical practice, they
would base their decisions on treatment response evi-
dence, e.g. from clinical assessment, observations, cultures
and inflammatory markers. However, one important as-
pect of clinical management is that antibiotics are gener-
ally initiated by the admitting clinical team, with a
different clinical team responsible for ‘review and revise’
48–72 h later. The lack of clear understanding about the
reason that antibiotics were initially started is one specific
aspect that the ARK-Hospital programme is designed to
address [32]. Some respondents also said that, in real life,
levels of harm from continuing/discontinuing antibiotics
are harder to quantify and felt that the availability of the
explicit percentage risks was an oversimplification. Only a
third of respondents provided qualitative data however,
and they may not have been typical of the whole sample.
Though it is noteworthy that consultants chose to con-
tinue prescribing less often than non-consultants, an ana-
lysis of which professional factors are related to
continuing antibiotics when they should actually be dis-
continued was beyond the scope of this study. This would
potentially be a valuable avenue for future research.
Conclusions
In this study we have quantified the relative import-
ance of factors likely to play a key role in ‘review and
revise’ decisions on (dis) continuing antibiotics in
hospitals. Our results are suggestive of several poten-
tial barriers to safe early discontinuation of antibi-
otics, with early discontinuation ‘strongly conflicting’
with local guidelines being key. Revising guidelines to
be less prescriptive about duration, and instead mak-
ing duration conditional on patient factors and treat-
ment response, could help to safely increase the
frequency of early discontinuation of antibiotics. Ad-
dressing the other barriers to early discontinuation
suggested by our results may be more challenging.
More research is urgently needed to identify and
quantify barriers and facilitators of safe early discon-
tinuation of antibiotics in other healthcare settings.
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